NCT07154901 2026-02-24
Investigation of the Effects of Renal Impairment on the Pharmacokinetics, Safety, and Tolerability of Opemalirsen (AZD2373)
AstraZeneca
Phase 1 Recruiting
Clinical Trials
11 trialsNCT03098589 2025-03-30
Revlimid® Capsules Drug Use-results Surveillance (Relapsed or Refractory ATLL)
Celgene
Completed
NCT02571036 2023-12-13
A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies
Deciphera Pharmaceuticals, LLC
Phase 1 Completed
NCT04656795 2023-05-15
PK Study in Subjects With Renal Impairment (Severe and if Required Mild & Moderate) Compared to Subjects With Normal Renal Function
Tanabe Pharma America, Inc.
Phase 1 Completed
NCT00652626 2019-11-19
RENAL
Celgene
Phase 1 Completed
NCT03097016 2018-04-26
A Study to Assess the Pharmacokinetics of CC-122 in Subjects With Mild, Moderate, and Severe Renal Impairment
Celgene
Phase 1 Completed
NCT01569815 2015-10-19
Pharmacokinetics of LCZ696 in Subjects With Mild and Moderate Renal Impairment Compared to Healthy Subjects With Normal Renal Function
Novartis
Phase 1 Completed
NCT00418366 2015-08-19
A Study on the Effect of Kidney Disease on a Diabetes Medication (0431-008)
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT01504165 2014-02-04
Pharmacokinetics in Subjects With Renal Impairment
Merck KGaA, Darmstadt, Germany
Phase 1 Completed
NCT00750620 2013-09-05
A Pharmacokinetic Study of YM178 in Normal Subjects and Those With Mild, Moderate, and Severe Renal Impairment
Astellas Pharma Inc
Phase 1 Completed
NCT01374113 2013-03-29
Safinamide Renal Impairment Trial
Newron Pharmaceuticals SPA
Phase 1 Completed